PharVision Advisers
INGN icon

PharVision Advisers’s Inogen INGN Stock Holding History

PharVision Advisers’s Portfolio INGN Stock Details INGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-13,473
Closed -$86.9K – 47
2026
Q2 		$86.9K Buy
+13,473
New +$89.2K 1.64% 27
2026
Q1 		– Sell
-55,240
Closed -$371K – 366
2025
Q4 		$371K Buy
+55,240
New +$414K 0.19% 149
2025
Q1 		– Sell
-18,885
Closed -$173K – 390
2024
Q4 		$173K Buy
+18,885
New +$177K 0.15% 333

Other funds holding INGN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
AlphaCore Capital
AlphaCore Capital La Jolla, California $6.24B AUM 19.96% 1-Year Est. Return

PharVision Advisers's INGN Position: Q3 2026 in Review

PharVision Advisers sold out of Inogen (INGN) in Q3 2026, closing a stake of 13,473 shares — an estimated $86.9K sold.

PharVision Advisers first reported a position in INGN in Q4 2024 and held it in 3 quarters. The position peaked at $371K in Q4 2025. 45 funds tracked by Wall St. Rank hold INGN as of Q3 2026.

  • PharVision Advisers reported no remaining Inogen position as of Q3 2026 after selling out during the quarter.
  • PharVision Advisers sold 13,473 Inogen shares in Q3 2026, an estimated $86.9K.
  • PharVision Advisers first reported a position in Inogen in Q4 2024 and held it in 3 quarters.
  • PharVision Advisers's Inogen position peaked at $371K in Q4 2025.
  • 45 funds tracked by Wall St. Rank held Inogen as of Q3 2026.

Based on PharVision Advisers's 13F filing for Q3 2026, filed 29 Oct 2026.